We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00354796
Recruitment Status : Unknown
Verified June 2011 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : July 20, 2006
Last Update Posted : July 6, 2011
Sponsor:
Information provided by:
Hadassah Medical Organization

Brief Summary:
We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Condition or disease
Acute Coronary Syndrome Venous Thromboembolism Atrial Fibrillation Hypercoagulability

Detailed Description:
Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin
Study Start Date : July 2006
Estimated Study Completion Date : October 2015






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients admitted to tertiary hospital
Criteria

Inclusion Criteria:

  • treatment with enoxaparin

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354796


Contacts
Contact: Mordechai Muszkat, MD 00-972-2-6776449 muszkatm@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD    00 972 2 6776095    arik@hadassah.org.il   
Contact: hadas Lemberg, PhD    00 972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Mordechai Muszkat, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Mordechai Muszkat, MD Hadassah University Hospital

Responsible Party: Mordechai Muszkat, Hadassah University Hospital
ClinicalTrials.gov Identifier: NCT00354796     History of Changes
Other Study ID Numbers: enoxap-HMO-CTIL
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: July 6, 2011
Last Verified: June 2011

Keywords provided by Hadassah Medical Organization:
bleeding
anticoagulation
LMWH
Enoxaparin

Additional relevant MeSH terms:
Thrombophilia
Atrial Fibrillation
Acute Coronary Syndrome
Thromboembolism
Venous Thromboembolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Embolism and Thrombosis
Hematologic Diseases